Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity

Breast Cancer Research

Volumn 10, Issue 4, 2008, Pages

  Howell, Sacha J ^a   Anderson, Elizabeth ^a,b   Hunter, Tom ^a   Farnie, Gillian ^a   Clarke, Robert B ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; DOXORUBICIN; LISSAMINE RHODAMINE B; MESSENGER RNA; PACLITAXEL; PROLACTIN; PROLACTIN RECEPTOR; RHODAMINE;

APOPTOSIS; ARTICLE; BREAST TUMOR; CHEMISTRY; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

AGAR; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA, COMPLEMENTARY; DOXORUBICIN; HUMANS; IMMUNOHISTOCHEMISTRY; PACLITAXEL; PROLACTIN; RECEPTORS, PROLACTIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHODAMINES; RNA, MESSENGER;

EID: 65849450483     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2129     Document Type: Article

References (39)

1. Acosta JJ, Munoz RM, Gonzalez L, Subtil-Rodriguez A, Dominguez-Caceres MA, Garcia-Martinez JM, Calcabrini A, Lazaro-Trueba I, Martin-Perez J. Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways. Mol Endocrinol 2003, 17:2268-2282. 10.1210/me.2002-0422, 12907754.
2. Manni A, Wright C, Davis G, Glenn J, Joehl R, Feil P. Promotion by prolactin of the growth of human breast neoplasms cultured in vitro in the soft agar clonogenic assay. Cancer Res 1986, 46:1669-1672. 3948157.
3. Maus MV, Reilly SC, Clevenger CV. Prolactin as a chemoattractant for human breast carcinoma. Endocrinology 1999, 140:5447-5450. 10.1210/en.140.11.5447, 10537179.
4. Peirce SK, Chen WY. Human prolactin and its antagonist, hPRL-G129R, regulate bax and bcl-2 gene expression in human breast cancer cells and transgenic mice. Oncogene 2004, 23:1248-1255. 10.1038/sj.onc.1207245, 14647416.
5. Schroeder MD, Symowicz J, Schuler LA. PRL modulates cell cycle regulators in mammary tumor epithelial cells. Mol Endocrinol 2002, 16:45-57. 10.1210/me.16.1.45, 11773438.
6. Boyns AR, Buchan R, Cole EN, Forrest AP, Griffiths K. Basal prolactin blood levels in three strains of rat with differing incidence of 7,12-dimethylbenz(a)anthracene induced mammary tumours. Eur J Cancer 1973, 9:169-171.
7. Welsch CW, Brown CK, Goodrich-Smith M, Van J, Denenberg B, Anderson TM, Brooks CL. Inhibition of mammary tumorigenesis in carcinogen-treated Lewis rats by suppression of prolactin secretion. J Natl Cancer Inst 1979, 63:1121-1124.
8. Wennbo H, Kindblom J, Isaksson OG, Tornell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997, 138:4410-4415. 10.1210/en.138.10.4410, 9322957.
9. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 2004, 64:6814-6819. 10.1158/0008-5472.CAN-04-1870, 15375001.
10. Tworoger SS, Eliassen AH, Sluss P, Hankinson SE. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007, 25:1482-1488. 10.1200/JCO.2006.07.6356, 17372279.
11. Gill S, Peston D, Vonderhaar BK, Shousha S. Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J Clin Pathol 2001, 54:956-960. 1731342, 11729217.
12. Lissoni P, Vaghi M, Villa S, Bodraska A, Cerizza L, Tancini G, Gardani GS. Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergoline. Anticancer Res 2003, 23:733-736.
13. Asai-Sato M, Nagashima Y, Miyagi E, Sato K, Ohta I, Vonderhaar BK, Hirahara F. Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment. Int J Cancer 2005, 115:539-544. 10.1002/ijc.20810, 15700312.
14. Gado K, Pallinger E, Kovacs P, Takacs E, Szilvasi I, Toth BE, Nagy G, Domjan G, Falus A. Prolactin influences proliferation and apoptosis of a human IgE secreting myeloma cell line, U266. Immunol Lett 2002, 82:191-196. 10.1016/S0165-2478(02)00008-1, 12036601.
15. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br J Cancer 2004, 91:305-311.
16. Woody E, Ben-Jonathan N. Prolactin antagonizes taxol cytotoxicity in breast cancer cells. 87th Annual Meeting of The Endocrine Society: June 4-7th 2005; San Diego
17. Ginsburg E, Vonderhaar BK. Prolactin synthesis and secretion by human breast cancer cells. Cancer Res 1995, 55:2591-2595.
18. Reynolds C, Montone KT, Powell CM, Tomaszewski JE, Clevenger CV. Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 1997, 138:5555-5560. 10.1210/en.138.12.5555, 9389544.
19. Goffin V, Struman I, Mainfroid V, Kinet S, Martial JA. Evidence for a second receptor binding site on human prolactin. J Biol Chem 1994, 269:32598-32606.
20. Chen WY, Ramamoorthy P, Chen N, Sticca R, Wagner TE. A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis. Clin Cancer Res 1999, 5:3583-3593.
21. Llovera M, Pichard C, Bernichtein S, Jeay S, Touraine P, Kelly PA, Goffin V. Human prolactin (hPRL) antagonists inhibit hPRL-activated signaling pathways involved in breast cancer cell proliferation. Oncogene 2000, 19:4695-4705. 10.1038/sj.onc.1203846, 11032019.
22. Tomblyn S, Langenheim JF, Jacquemart IC, Holle E, Chen WY. The role of human prolactin and its antagonist, G129R, in mammary gland development and DMBA-initiated tumorigenesis in transgenic mice. Int J Oncol 2005, 27:1381-1389.
23. Bernichtein S, Kayser C, Dillner K, Moulin S, Kopchick JJ, Martial JA, Norstedt G, Isaksson O, Kelly PA, Goffin V. Development of pure prolactin receptor antagonists. J Biol Chem 2003, 278:35988-35999. 10.1074/jbc.M305687200, 12824168.
24. Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, Li H, Nurmi M, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Goffin V, Nevalainen MT. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology 2007, 148:3089-3101. 10.1210/en.2006-1761, 17412813.
25. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82:1107-1112. 10.1093/jnci/82.13.1107, 2359136.
26. Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson NG, Bundred NJ. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 2007, 99:616-627. 10.1093/jnci/djk133, 17440163.
27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685. 10.1038/227680a0, 5432063.
28. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000, 342:1171-1177. 10.1056/NEJM200004203421604, 10770982.
29. Biswas R, Vonderhaar BK. Role of serum in the prolactin responsiveness of MCF-7 human breast cancer cells in long-term tissue culture. Cancer Res 1987, 47:3509-3514.
30. Zinger M, McFarland M, Ben-Jonathan N. Prolactin expression and secretion by human breast glandular and adipose tissue explants. J Clin Endocrinol Metab 2003, 88:689-696. 10.1210/jc.2002-021255, 12574200.
31. Ruffion A, Al-Sakkaf KA, Brown BL, Eaton CL, Hamdy FC, Dobson PR. The survival effect of prolactin on PC3 prostate cancer cells. Eur Urol 2003, 43:301-308. 10.1016/S0302-2838(03)00038-1, 12600435.
32. Brunetti L, Orlando G, Michelotto B, Recinella L, Ragazzoni E, Vacca M. A possible prolactin-related adverse effect of certain antineoplastic anthracyclines. Toxicol Lett 2000, 116:231-236. 10.1016/S0378-4274(00)00223-X, 10996485.
33. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA, Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005, 65:5506-5511. 10.1158/0008-5472.CAN-05-0626, 15994920.
34. van Nimwegen MJ, Huigsloot M, Camier A, Tijdens IB, Water B. Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells. Mol Pharmacol 2006, 70:1330-1339. 10.1124/mol.106.026195, 16825486.
35. Vigneron A, Roninson IB, Gamelin E, Coqueret O. Src inhibits adriamycin-induced senescence and G2 checkpoint arrest by blocking the induction of p21waf1. Cancer Res 2005, 65:8927-8935. 10.1158/0008-5472.CAN-05-0461, 16204065.
36. Gutzman JH, Rugowski DE, Schroeder MD, Watters JJ, Schuler LA. Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells. Mol Endocrinol 2004, 18:3064-3075. 1634796, 15319452, 10.1210/me.2004-0187.
37. Kabotyanski EB, Rosen JM. Signal transduction pathways regulated by prolactin and Src result in different conformations of activated Stat5b. J Biol Chem 2003, 278:17218-17227. 10.1074/jbc.M301578200, 12621061.
38. Kazansky AV, Kabotyanski EB, Wyszomierski SL, Mancini MA, Rosen JM. Differential effects of prolactin and src/abl kinases on the nuclear translocation of STAT5B and STAT5A. J Biol Chem 1999, 274:22484-22492. 10.1074/jbc.274.32.22484, 10428824.
39. Liby K, Neltner B, Mohamet L, Menchen L, Ben-Jonathan N. Prolactin overexpression by MDA-MB-435 human breast cancer cells accelerates tumor growth. Breast Cancer Res Treat 2003, 79:241-252. 10.1023/A:1023956223037, 12825859.